FAKTEN NEWS und Wissenswertes über SINOBIOMED (G8U) - 500 Beiträge pro Seite

[RGmotte]

hallo zusammen

um eine Übersichtlicheres Bild von SINOBIOMED (G8U) bitte hier nur wie in der Überschrift schon beschrieben FAKTEN NEWS und WISSENSWERTES, UNTERNEHMENSDATEN und co eintragen.

danke natürlich Quelle bestärken die Aussagekraft

[RGmotte]

SinoBiomed’s Management Team, Key Advisors and Consultants

SinoBiomed has assembled an integrated team with proven financial, corporate development, scientific and production skills at the international level to cost-effectively develop and deploy biopharmaceuticals that can bring shareholder significant and sustained return on investment.

President Banjun Yang, President and CEO. Mr. Yang has more than 25 years of experience in entrepreneurial and investment management in Hong Kong, Beijing and Shanghai. He served as Chairman of the Board and General Manager for Shanghai Wanxing Bio-Pharmaceutical Co. Ltd. from 1996 to 2006, and from 1991 to the present as Chairman of Hong Kong Wanxing Enterprises. In the 1990s, he was Chairman of Shanghai Wanxing Automobile Service Co. Ltd. and Beijing Automobile Service Co. Ltd. following service in senior positions in the late 1980s at the Shenzhen Beijing Hotel and at the Shenzhen Nabei Trade Centre.

Christopher Metcalf, Director; Chair of Audit Committee. Mr. Metcalf is an investment professional with experience in venture capital, investment banking, commercial banking and all aspects of financial analysis. He has served as Vice President of the Graystone Research Group of Morgan Stanley in New York, President of Altitude Funds LLC, Vice President of KMV Capital, and Vice President and Senior Financial Analyst with Charles Schwab’s Family office. Mr. Metcalf is a member of both the Virginia and California State Bar Associations. He received a BSc in Commerce and a Juris Doctor degree from the University of Virginia, and an MBA from the University of Chicago.

Zhong Zhuang, Vice General Manager. Mr. Zhuang trained as a medical doctor at the Second Military Medical School in Shanghai and practiced for five years before obtaining his MBA from Fudan University. He has served as Vice General Manager for Shanghai Wanxing Bio-Pharmaceutical Co. Ltd. since 2002. Prior to that he was the Vice General Manager at United Gene Science and Technology in Shanghai and the Manager of Shanghai Likang Science Investment Enterprise.

Dr. Zhifang Cao, Deputy Vice General Manager. Dr. Cao integrates an extensive clinical background with a market-driven approach to identifying and developing bio-pharmaceuticals with strong therapeutic as well as profit potential. He joined the Company in 1999 and is responsible for planning and directing new drug development. A former Associate Professor and Director of Research and Development at Second Military Medical Hospital in Shanghai, Dr. Cao has more than 15 years of clinical experience, exceptional organizational ability and well-developed relationships in the bio-pharmaceutical industry. He earned his MD from Harbin University in 1984 and completed MBA studies at the Shanghai Cadre Training Center in 2001.

Xiudong Huang, Manager of Research and Development. Mr. Huang, a molecular biologist, has been involved in the development of some 15 recombinant protein drugs since 1998 and holds two Chinese patents, with another eight patents applied for. He joined the Company in 2001 to manage R&D, with responsibility for project selection, construction of host cells and new drug processing, including fermentation, purification and formulation steps. Prior to that he served as an associate professor in the Medical College of Anhui Science and Technology University, doing both research and teaching. He earned his Master’s Degree in Molecular Biology from the University of Science and Technology of China.

Mrs. Pan Xuegong, Quality Control Director. Mrs. Xuegong has more than 15 years of experience in pharmaceutical quality control. She joined the Company in 1999 and oversees the analysis, specification, quality control, application and registration of new drugs and bio-products using a series of assays and GMP processes that meet Chinese FDA requirements. She graduated from China Pharmaceutical University with a Bachelor Degree and obtained a Master’s Degree in Pharmacy at Shanghai Second Military Medical University.

Advisors and Consultants

Dr. Tom (Dwun-Hou) Chen, Chief Technical Consultant. Dr. Chen, Vice President of Process Development at Prometic BioTherapeutics in Rockville, Maryland, also serves as a consultant to the Program for Appropriate Technology in Health (PATH) in leading the process development and the manufacturing programs for SinoBiomed’s recombinant malaria vaccine. In addition to consulting for several private biotech companies, Dr. Chen has also served as the Director of Process Development for Plasma Derivatives for the American Red Cross. He obtained his BSc in Chemistry from Tamkang University, Taiwan, R.O.C., and his Ph.D. in Biochemistry from Auburn University.

Dr. Weiqing Pan, Advisor. Professor Dr. Pan, an internationally recognized researcher with more than 30 articles published in leading medical and scientific journals, heads the Department of Parasitology at the Second Military Medical University and serves on China’s national committee to combat parasitic diseases. Professor Pan is the inventor of the patented plasmodium fusion antigen that SinoBiomed is developing and testing as a blood-stage malaria vaccine with the support of the World Health Organization (WHO) and Program for the Appropriate Technology in Health (PATH). Professor Pan has won more than $2 million in research grants and is a frequent speaker at international conferences.

Jianzhi Xiang, Consultant. Mr. Xiang has been involved in the research, development and evaluation of bio-pharmaceutical and bio-products since 1961. He currently serves as a Panel Member of Expert Committee of Biological Standardization for the World Health Organization and has served as a consultant to public and private sector organizations, including Life Biotechnologies of Maryland and the Chinese Food and Drug Administration’s Center for Drug Evaluation. Mr. Jiang also has more than 30 years experience working as an investigator in biologicals, serving most recently as Principal Investigator and Chairman of the Expert Committee on Science and Technology, Shanghai Institute of Biological Products. He earned a Bachelor’s Degree in Chemistry from the University of Nanking in 1951.

Professor Yu-Yang Li, Advisor. Professor Li’s area of expertise is in foreign gene expression in yeast, a key element in the production process of SinoBiomed’s malaria vaccine. Professor Li conducts research in generic engineering and teaches molecular genetics and yeast genetic engineering at the Institute of Genetics of Fudan University in Shanghai. A former Dean of Fudan’s School of Life Sciences and Member of Expert Committee on the Field of Biotechnology of the National High-Tech Program in China, he continues to serve as a Drug Evaluation Expert for China’s State Drug Administration.

Dr. Dicken Shiu-Chung Ko, Advisor. Dr. Ko is an internationally recognized authority in kidney and pancreas transplantation. He is currently the Director of Adult Renal Transplantation at Massachusetts General Hospital, Assistant Professor of Surgery at Harvard Medical School and Chair of the Scientific Program of the Urological Society for Transplantation. A fellow of the American College of Surgeons, he has also received Specialty Board Certification in Urology from the Royal College of Physicians and Surgeons of Canada. He received a BSc from the University of British Columbia, an MD from Queen’s University and has undertaken postdoctoral training in surgery, urology, clinical transplantation and transplantation.


http://www.sinobiomed.com/management.htm

[RGmotte]

SinoBiomed’s current growth strategy focuses on innovative recombinant protein biopharmaceutical drug discovery, development, manufacture and distribution. We focus on targeted high potential therapy areas to serve clinical needs that are unmet or underserved by current products. SinoBiomed also actively seeks acquisitions that enhance or expand product development and/or marketing and would be accretive to shareholder value.

In executing this strategy, the Company leverages current assets that include:

* extensive intellectual capital, research and development resources
* strong university and research centre alliances, both domestic and international
* highly skilled proven drug discovery and development talent pool
* established integrated research and manufacturing facilities that meet GMP
* patented low-cost, high yield production process
* strong government and international agency support through funding and co-development agreements


http://www.sinobiomed.com/growth_strategy.htm

[RGmotte]

SINOBIOMED - CANCELLATION OF SHARES BY MAJOR STOCKHOLDER

Shanghai, China – March 15, 2007 – Sinobiomed Inc. (the “Company”) (OTCBB: SOBM) (formerly named CDoor Corp.) announces that its major stockholder, Mr. Ka Yu, who holds approximately 80,000,000 shares of common stock post forward stock split, has voluntarily surrendered for cancellation 76,000,000 shares. Prior to the closing of the Share Purchase Agreement between the Company, Wanxin Bio-Technology Limited (“Wanxin”) and the shareholders of Wanxin, which occurred on January 12, 2007, Mr. Ka Yu voluntarily agreed to surrender for cancellation 95% of the shares registered in his name after the Share Purchase Agreement completed and the Company held its shareholders meeting in order to encourage the shareholders of Wanxin to complete the Share Purchase Agreement and to allow Mr. Ban-Jun Yang to become the major shareholder of the Company. The cancellation of these 76,000,000 shares will reduce the issued and outstanding shares from 191,000,000 to 115,000,000.

As a correction for the news release issued on March 2, 2007 we would like to advise that Dr. Tom Chen serves as the Chief Technical Consultant of Shanghai Wanxing Bio-pharmaceuticals Co., Ltd. rather than Chief Medical Officer as previously stated.

http://www.sinobiomed.com/investors_news_releases_20070315_1…

[RGmotte]

rhaFGF PRODUCT RECEIVED NEW DRUG CERTIFICATE

Shanghai, China – April 11, 2007 – Sinobiomed Inc. (the “Company”) (OTCBB: SOBM) is pleased to announce that one of Shanghai Wanxing Bio-pharmaceuticals Co., Ltd.’s (“Shanghai Wanxing” – an 82% owned subsidiary of the Company) products, lyophilized recombinant human acidic fibroblast growth factor for external use (rhaFGF), which was awaiting approval from the Chinese State Food and Drug Administration (the “Chinese SFAD”), has recently been approved for new biotherapeutic and received a New Drug Certificate. Shanghai Wanxing is now awaiting GMP Certification. Shanghai Wanxing anticipates fabricating and distributing this product in the last half year of 2007. As approved by the Chinese SFDA, rhaFGF is a drug for the treatment of ulceration including deep burns (more than 2nd degree burns) and chronic ulcers caused by wounds, diabetes, vascular diseases and bed sores.



NEWS RELEASE


SINOBIOMED INC. SUBSIDIARY SIGNS TECHNICAL COOPERATION AGREEMENT WITH TAIWANESE BIOTECH

Shanghai Wanxing Bio-pharmaceuticals to investigate development of mass production for world’s first recombinant protein to stimulate angiogenesis – the development of new blood vessels

Shanghai, China – April 16 2007 – SinoBiomed Inc. (the “Company”) (OTCBB: SOBM) is pleased to announce that Shanghai Wanxing Bio-pharmaceuticals Co., Ltd.’s (“Shanghai Wanxing” – an 82% owned subsidiary of the Company) has signed a technical cooperation agreement with Blue Blood Biotech Corp. of Taiwan (“Blue Blood Biotech”).

The agreement calls for Blue Blood Biotech to pay Shanghai Wanxing $400,000 for conducting a development investigation into the mass production of recombinant NEFG protein. NEFG is the world’s first protein drug to stimulate angiogenesis, the development of new blood vessels. The drug, developed to treat diabetes patients, is set to undergo clinical testing with assistance from a biotechnology program under the Taiwan’s Ministry of Economic Affairs.

NEFG was cooperatively developed by Blue Blood and Professor Wu Hua-lin of Taiwan’s Chengkung University over a 10-year span, according to Blue Blood Biotech’s CEO Chiang Chuna-Chi. In 2004, NEFG was licensed for commercial development to Blue Blood, which is located in the Central Taiwan Science Park.

Shanghai Wanxing has advanced expertise in the mass production of recombinant proteins. It will conduct the development investigation in its certified GMP facilities, which have extensive fermentation and purification equipment as well as one of China’s largest capacities for the manufacture of recombinant bio-products.


SINOBIOMED INC. – CORRECTIVE NEWS RELEASE FOR WEBSITE OF BLUE BLOOD BIOTECH CORP.

Shanghai, China – April 17 2007 – SinoBiomed Inc. (the “Company”) (OTCBB: SOBM). Further to the news release of April 16, 2007, the Company would like to make the following correction: The website address for Blue Blood Biotech Corp. was incorrectly stated and the proper website should be www.blueblood.com.tw.

http://www.sinobiomed.com/news_releases.htm

[RGmotte]

SINOBIOMED’S MALARIA VACCINE GRANTED US PATENT

(Shanghai, China – April 24, 2007) SinoBiomed Inc. ("SinoBiomed", "the Company") (OTCBB: SOBM) is pleased to announce that the United States Patent and Trademark office has granted a patent for the malaria vaccine PfCP2.9 to which SinoBiomed has exclusive rights to develop, manufacture and sell through its 82 percent owned subsidiary, Shanghai Wanxing Bio-pharmaceuticals Co. Ltd. ("Shanghai Wanxing").

Patent number 7,101,556 B2, dated September 5, 2006, has been assigned to the Second Military Medical University (SMMU) of Shanghai China for the preparation and dosage of plasmodium fusion antigen invented by Dr. Weiqing Pan. Dr. Pan, an advisor to SinoBiomed and an internationally recognized researcher, heads the Department of Parasitology at SMMU and serves on China’s national committee to combat parasitic diseases.

"The granting of this US patent enables SinoBiomed to proceed with the vaccine development with full confidence in its potential for commercial development for the global market," said Company President and CEO Banjun Yang. "The potential benefits to humanity as well as to SinoBiomed shareholders are significant."

The invention provides a fusion protein comprising the Plasmodium merozoite surface protein-1 (MSP1) and the Plasmodium apical membrane antigen 1 (AMA-1), the encoding DNA sequence, the vector containing the sequence, the host cell containing the vector and the genetic engineering method for preparing the fusion protein and the usage for producing anti-malarial vaccine. The patent holder was granted the right to exclude others from making, using, offering for sale, or selling the invention throughout the United States with 20 years protection term from the date on which the earliest application was filed (February 1, 2002).

On Mar 22, 2001, Second Military Medical University and Shanghai Wanxing signed the authorization letter that gives Shanghai Wanxing the exclusive right to exploit such technology, including the right to manufacture and sell the malaria vaccine it develops. SinoBiomed is developing and testing the plasmodium fusion antigen as a blood-stage malaria vaccine with the support of the World Health Organization (WHO) and the Malaria Vaccine Initiative (MVI) of the Program for the Appropriate Technology in Health (PATH). The Bill & Melinda Gates Foundation has committed $258.3 million to the global fight to eradicate malaria.
SinoBiomed’s malaria candidate vaccine (PfCP2.9) targets the world’s most deadly malaria parasite (Plasmodium falciparum) at its most destructive stage—its rapid replication in human red blood cells. In the now completed Phase I Clinical Trial, PfCP2.9 showed high immunogenicity and mild adverse events. The Chinese State Food and Drug Administration (SFDA), which has a drug approval process similar to that of the US FDA, has approved PfCP2.9 for Phase II Clinical Trial to be conducted in China’s Yunnan Province and Southeast Asia.



SinoBiomed Subsidiary's Production Facility Recertified by Chinese State Food and Drug Administration

SHANGHAI, CHINA - 05/09/07 - SinoBiomed Inc. ("SinoBiomed", "the Company") (OTCBB: SOBM) is pleased to announce that the Chinese State Food and Drug Administration (SFDA) has recertified the recombinant human interferon production plant of Shanghai Wanxing Bio-pharmaceuticals Co. Ltd. (SinoBiomed's 82-percent owned subsidiary) as a Good Manufacturing Practice (GMP) facility.

The 2,500-square-meter plant passed the local GMP re-certification inspection that the SFDA conducted from April 12 to 14, 2007 in Shanghai. The facility produces recombinant human interferon powder for injection. Recombinant human interferon is widely used for treating chronic hepatitis B, hepatitis C, a number of viral infections, and tumors.

In meeting Chinese national drug GMP certification standards, the plant's heating ventilation air conditioning system achieved a grade of 100 in the SFDA's air cleanliness classification, equivalent to a B grade in the U.S. air cleanliness classification.

The facility has one of China's largest production capacities and has produced some 12 million doses of recombinant human interferon since its initial five-year certification on December 12, 2001. The re-certification authorizes production for another five-year term, ensuring quality control for the product as Shanghai Wanxing expands national and international distribution.

[RGmotte]

PROF. ZHI-XIN WANG, Ph.D. JOINS SINOBIOMED INC. AS A DIRECTOR

TSINGHUA UNIVERSITY SCIENTIST INTERNATIONALLY RECOGNIZED FOR EXPERTISE IN ENZYMOLOGY

Shanghai, China – May 15, 2007 – Sinobiomed Inc. ("Sinobiomed", or the "Company") (OTCBB: SOBM) is pleased to announce that Professor Zhi-Xin Wang of the Department of Biological Sciences and Biotechnology at Beijing's Tsinghua University has joined Sinobiomed's Board of Directors. Tsinghua is generally ranked as China's leading university for science and engineering.

Prof. Wang, globally recognized for his expertise in enzymology, has published 68 articles in English in international scientific journals. He is the Chair of the Chinese Society of Biochemistry and Molecular Biology, and a member of the Chinese Society of Biophysics as well as the Chinese Academy of Sciences.

"Sinobiomed is very fortunate to have a scientist of Prof. Wang's stature accept membership on the Board," said Company President and CEO Ban Jun Yang. "His knowledge and relationships will be invaluable in expanding and strengthening Sinobiomed's research and development capabilities."

After receiving his Ph.D. at China's Institute of Biophysics and teaching there and at Tsinghua University, Prof. Wang undertook postdoctoral study in the U.S. at Cornell University and North Dakota State University. Upon his return, he served as a Professor at the Institute of Biophysics, Academia Sinica, and as a Director at both the National Laboratory of Biomacromolecules and the Institute of Biophysics, Academia Sinica, before returning to Tsinghua in 2004.


SINOBIOMED SIGNS LETTER OF INTENT TO ACQUIRE PHARMACEUTICAL DISTRIBUTOR

Acquisition Would Give SinoBiomed Control of SFDA GSP Certified pharmaceutical distributor and expand market reach throughout China

Shanghai, China – May 23, 2007 – Sinobiomed Inc. (“Sinobiomed”, or “the Company”) (OTCBB: SOBM) is pleased to announce that its 82% owned subsidiary, Shanghai Wanxing Bio-pharmaceuticals Co., Ltd. (“Shanghai Wanxing”), has signed a letter of intent with the equity owners of Suzhou Baoi Medical Development Company (“Suzhou Baoi”) to acquire their company.

The acquisition is to be accomplished through an equity transfer of not less than 80% from the equity owners of Suzhou Baoi to Shanghai Wanxing. The transfer, when completed, would give Shanghai Wanxing control of Suzhou Baoi, which is GSP certified by the Chinese FDA (SFDA). The SFDA is modeled on the U.S. FDA. GSP stands for Good Supply Practice, and certification safeguards the safety and quality of pharmaceutical products in business transactions.

Suzhou Baoi’s total 2006 sales revenue was approximately 170 million RMB (US $21 million). The pharmaceutical distribution company, located in Suzhou, about 100 km east of Shanghai, has two wholly owned subsidiaries; one sells vaccines, the other medical devices. Suzhou Baoi is engaged in the wholesale supply of biological products, chemical medicines and Chinese traditional medicine.

Shanghai Wanxing’s 3,000 sq. meter manufacturing plant in Shanghai already has SFDA GMP certification. GMP stands for Good Manufacturing Practice, which focuses on product quality and hygiene practice during the manufacturing process.

“The acquisition of Suzhou Baoi’s well developed product distribution network – in combination with Shanghai Wanxing’s existing products, robust product pipe line and GMP certification, is expected to accelerate and expand sales and revenue throughout China,” according to Shanghai Wanxing President and CEO, Banjun Yang.

The letter of intent, signed May 22, 2007, stipulates that the formal transfer agreement will be executed one month after the signing. The terms of the agreement call for an equity transfer of not less than 80% from the equity owners of Suzhou Baoi to Shanghai Wanxing. The transfer price is initially set at two times Suzhou Baoi’s authorized capital of RMB10 million, about US $2.5 million. The final transfer price, however, shall be determined depending on a financial audit report.

SINOBIOMED'S INTERNATIONAL PATENT APPLICATION FOR RECOMBINANT BATROXOBIN (rBAT) ACCEPTED

rBAT IS WORLD'S FIRST BATROXOBIN SYNTHESIZED THROUGH GENE RECOMBINATION; NATURAL BATROXOBIN IS WORLD'S MOST PRESCRIBED ANTI-BLEEDING AGENT

(Shanghai, China – May 29, 2007) Sinobiomed Inc. ("Sinobiomed", or "the Company") is pleased to announce that the Patent Cooperation Treaty (PCT) has accepted the patent application for "a purified recombinant batroxobin with high bioactivity" made by Shanghai Wanxing Bio-pharmaceuticals Co., Ltd. ("Shanghai Wanxing"), the Company's 82% owned subsidiary.

The PCT issued the Sinobiomed invention – known as rBAT, or recombinant batroxobin -- international application number PCT/CN2007/001036 on March 30, 2007.

The invention comprises a DNA recombinant technology to fabricate batroxobin, which exists naturally in the venom of the pallas pit viper. The invention also covers the synthesis of the batroxobin gene, as well as the expression, purification and characterization of batroxobin. Shanghai Wanxing applied for a Chinese patent for rBAT in 2003.

Natural batroxobin is the world's most prescribed biological anti-bleeding agent, but also has high production costs and safety concerns. In China, natural batroxobin currently has more than 80 percent of the domestic market.

rBAT is the world's first batroxobin synthesized through gene recombination. Shanghai Wanxing's low-cost, high-yield production process enhances bioactivity and guarantees the highest levels of purity. Shanghai Wanxing developed rBAT to prevent and treat surgical bleeding; it is now in Phase II Clinical Trials.
"The Patent Treaty Commission's acceptance of our international patent application for recombinant batroxobin confirms Sinobiomed's ability to identify unmet or underserved medical needs and develop innovative, patentable products to meet them," said Company President and CEO Banyun Yang.


SINOBIOMED UPDATES ON CLINCIAL TRIAL PROGRESS FOR RECOMBINANT BATROXOBIN (rBAT)

(Shanghai, China – July 10, 2007) Sinobiomed Inc. (“Sinobiomed”, or “the Company”) is pleased to update on clinical trial progress for the recombinant batroxobin (rBAT) made by Shanghai Wanxing Bio-pharmaceuticals Co., Ltd. ("Shanghai Wanxing"), the Company’s 82% owned subsidiary.

Sinobiomed’s Chinese-patented rBAT is world’s first batroxobin to be synthesized through gene recombination. Natural batroxobin is world’s most prescribed anti-bleeding agent. The Patent Cooperation Treaty (PCT) issued rBAT an international application number in March 2007.

The Phase II Clinical Trial, launched in November 2006, has two steps. The first step, now completed, tested rBAT”s effectiveness as an anti-bleeding agent at different dosages during general surgery compared to that of a placebo. The first step had 120 people enrolled.

The Company has now completed the design necessary for the second step of the Phase II Clinical Trial, which will involve 400 patients. The second step will compare rBAT’s efficacy to that of natural batroxobin in patients undergoing gynecological surgery, those with menorrhagia, excessive or prolonged menstrual bleeding, and those with gastrointestinal bleeding not associated with surgery.

A positive result in the second step would increase the number of applications for rBAT, widening the market for potential sales.





NEWS RELEASE
FOR IMMEDIATE RELEASE

SINOBIOMED SUBSIDIARY COMMENCES PRODUCTION OF RECOMBINANT ACIDIC FIBROBLAST GROWTH FACTOR (aFGF)

Shanghai, China – July 18, 2007 - Sinobiomed Inc.(the "Company") (OTCBB:SOBM) is pleased to announce that Shanghai Wanxing Bio-pharmaceuticals Co., Ltd.’s ("Shanghai Wanxing" – an 82% owned subsidiary of the Company) has commenced production of recombinant acidic Fibroblast Growth Factor (aFGF). Shanghai Wanxing’s production facility for aFGF recently received its GMP (Good Manufacturing Practice) Certification by the Chinese SFDA. As approved by the Chinese SFDA, aFGF is a drug for the treatment of ulceration including deep burns (more than 2nd degree burns) and chronic ulcers caused by burn wounds, diabetes, vascular diseases and bed sores. aFGF is expected to enter the market in August 2007 with a production volume of approximately 20 million boxes per year and will retail for US $15.5/box. At present 200 distributors are negotiating with the company to distribute the product.

Shanghai Wanxing’s aFGF was granted a Chinese patent license in September of 2004 with protection period for 20 years. As approved by the SFDA, this product will be officially protected as a new drug for a period of 7 years, which means that during this time the SFDA will not accept any other company’s new drug application of aFGF in China.

alle news von hier

http://www.sinobiomed.com/news_releases.htm

[RGmotte]

wäre schön wenn dies weiter mit Zahlen und Fakten um und über die sino gefüttert wird.

[RGmotte]

SinoBiomed currently has four products in clinical trials.

* Recombinant Malaria Vaccine
* Recombinant Batroxobin (rBAT)
* Recombinant Human Stem Cell Factor (SCF)
* Ethelphazine

Recombinant Malaria Vaccine

SinoBiomed’s malaria candidate vaccine (PfCP2.9) targets the world’s most deadly malaria parasite (Plasmodium falciparum) at its most destructive stage—its rapid replication in human red blood cells. In the now completed Phase I Clinical Trial, PfCP2.9 showed greater immunogenicity and fewer adverse reactions than other malaria candidate vaccines overseas. The Chinese State Food and Drug Administration (SFDA), which has a drug approval process similar to that of the US FDA, has approved PfCP2.9 for Phase II Clinical Trial to be conducted in Ghana in summer 2007.

Phase I Clinical Trial Summary

The goal for PfCP2.9 is to create a blood stage vaccine (asexual stage). The vaccine aims to reduce the parasite densities in the blood and could be able to reduce the morbidity and mortality of the malaria in infants and children. The goal of the trial was to assess the vaccine’s safety and conduct a preliminary evaluation of its immunogenicity. A total of 52 volunteers were enrolled; 40 of them received the vaccine and 12 received a placebo. The trial was a dose escalation, placebo controlled (ISA 720 adjuvant) study. Each volunteer received three intramuscular injections with 0.5 ml per injection.

The results of WAN/Mal-001 showed:

* No vaccine related severe adverse events
* Mostly mild or moderate local adverse events
* Mid-high antibody titers generated in four dose groups
* No dose response effects were observed.

The Phase I Clinical Trial took place from August 2003 to October 2004 at the Shanghai Changhai Hospital. Sponsored by Wanxing Bio-Pharmaceuticals, SinoBiomed’s Chinese subsidiary, the trial was funded by the World Health Organization (WHO), with the protocol reviewed and approved by WHO’s Ethics Committee.

Support for Vaccine Development

The Company’s development of the recombinant malaria blood-stage vaccine is receiving support from:

* The Malaria Vaccine Initiative (MVI / www.malariavaccine.org) of the Program for Appropriate Technology in Health (PATH / www.path.org). PATH/MVI is funding clinical trials for the malaria vaccine that SinoBiomed has exclusive rights to develop. The PATH/MVI-SinoBiomed partnership focuses on improving the manufacturing process as part of the vaccine’s safety evaluation, a critical step in the clinical development plan to generate proof that PfCP2.9) can impact the parasite in children.
* The World Health Organization (WHO / www.who.int) is promoting collaboration among public and private organizations in malaria vaccine development through its Initiative for Vaccine Research (IVR / www.who.int/vaccine_research/en/). The WHO/IVR has signed a memorandum of understanding with SinoBiomed to collaborate on the vaccine’s development and worldwide distribution.
* The Bill & Melinda Gates Foundation, which to date has donated $257.6 million to PATH/MVI.

Malaria: A Global Disease

Malaria threatens more than 2 billion people globally and kills more than a million people a year – most of them children. In Africa, malaria causes the death of a child every 30 seconds. The most important tropical disease, malaria remains widespread throughout the tropics, but also occurs in many temperate regions. It exacts a heavy toll of illness and death, especially among children and pregnant women. It also poses a risk to travelers and immigrants, with imported cases increasing in non-endemic areas. Treatment and control have become more difficult with the spread of drug-resistant strains of parasites and insecticide-resistant strains of mosquito vectors. Malaria exists in 100 countries but is mainly confined to poorer tropical areas of Africa, Asia and Latin America. More than 90% of malaria cases and the great majority of malaria deaths occur in tropical Africa.

- back to top -

Recombinant Batroxobin (rBAT)

The world’s first batroxobin synthesized through gene recombination, prevents and treats surgical bleeding. Natural batroxobin, extracted from snake venom, is the world’s most prescribed biological anti-bleeding agent, but also has a high production cost and safety concerns. A patent-applied-for bio-product, rBAT is in Phase II Clinical Trial.

- back to top -

Recombinant Human Stem Cell Factor (SCF)

A patent-applied-for bio-product in Phase 1 Clinical Trial that facilitates recovery of blood cell regeneration following radio-chemotherapy treatment in patients with malignant tumors.

- back to top -

Ethelphazine

A patent-applied-for anti-tumor drug entering Phase III Clinical Trial in fall 2006. Ethelphazine has wide-spectrum anti-tumor activity, high potency, low toxicity and chemical stability. Patented in China, it is now in Phase III clinical trial and expected to enter the market by the end of 2007. In the Phase II clinical trial of Ethelphazine, clinical indications have been expanded to lung cancer and malignant tumors of gastrointestinal tract besides malignant lymphoma. The incidence of malignant lymphoma ranks 9th to 11th among all tumors and is increasing each year. In China, there are 25,000 new cases of malignant lymphoma each year. There are about 480,000 lung cancer cases, i.e. 16% of all tumors cases in China, and the incidence of lung cancer is increasing each year.

Market Analysis

Cancer is now the leading cause of death in China. An estimated 6.3 million people die from cancer each year and the figure may double by 2020. The total annual sale of anti-tumor drugs in China is currently $1 billion and the market capacity for anti-tumor drugs is to grow by 17% to 20% in the next few years. There are about 1.6 million new tumor patients every year in addition to the 1.4 million patients under treatment.

http://www.sinobiomed.com/clinical_trials.htm

[RGmotte]

PRODUCT PIPELINE| RESEARCH AND DEVELOPMENT


Recombinant hepato regeneration factor for acute liver failure

Recombinant Human Type 1 Kallikrein for peripheral vascular disorders

Recombinant Human Urinary Trypsin inhibitor for acute pancreatitis

http://www.sinobiomed.com/research_development.htm

[RGmotte]

PRESS RELEASE

FOR IMMEDIATE RELEASE



SinoBiomed’s malaria vaccine granted european patent



NEW PATENT PROVIDES PROTECTION

IN UP TO 37 COUNTRIES IN EUROPE



(Shanghai, China – July 25, 2007) Sinobiomed Inc. (“Sinobiomed”, “the Company”) (OTCBB: SOBM) is pleased to announce that the European Patent Office (EPO) has granted a patent for the malaria vaccine PfCP2.9 to which Sinobiomed has exclusive rights to develop, manufacture and sell through its 82 percent owned subsidiary, Shanghai Wanxing Bio-pharmaceuticals Co., Ltd. (“Shanghai Wanxing”). The EPO provides patent protection in up to 37 European countries.



EPO patent number 1357128, dated July 4, 2007, has been assigned to the Second Military Medical University (SMMU) of Shanghai China for the preparation and dosage of plasmodium fusion antigen invented by Dr. Weiqing Pan. Dr. Pan, an advisor to Sinobiomed and an internationally recognized researcher, heads the Department of Parasitology at SMMU and serves on China’s national committee to combat parasitic diseases. The U.S. Patent and Trademark Office granted SMMU a patent for the plasmodium fusion antigen in September 2006.



“The granting of the European patent further strengthens Sinobiomed’s ability to proceed with the vaccine’s development with full confidence in its potential for commercial development for the global market,” said Company President and CEO Banjun Yang. “The potential benefits to humanity as well as to Sinobiomed shareholders are significant.”



The invention provides a fusion protein comprising the Plasmodium merozoite surface protein-1 (MSP1) and the Plasmodium apical membrane antigen 1 (AMA-1), the encoding DNA sequence, the vector containing the sequence, the host cell containing the vector and the genetic engineering method for preparing the fusion protein and the usage for producing anti-malarial vaccine. The patent holder was granted the right to exclude others from making, using, offering for sale, or selling the invention throughout Europe with 20 years protection term from the date on which the earliest application was filed (February 1, 2002).



On Mar 22, 2001, SecondMilitaryMedicalUniversity and Shanghai Wanxing signed a collaboration and license agreement that gives Shanghai Wanxing the exclusive right to exploit such technology, including the right to manufacture and sell the malaria vaccine it develops. Sinobiomed is developing and testing the plasmodium fusion antigen as a blood-stage malaria vaccine with the support of the World Health Organization (WHO) and the Malaria Vaccine Initiative (MVI) of the Program for the Appropriate Technology in Health (PATH).



Sinobiomed’s malaria candidate vaccine (PfCP2.9) targets the world’s most deadly malaria parasite (Plasmodium falciparum) at its most destructive stage—its rapid replication in human red blood cells. In the now completed Phase I Clinical Trial, PfCP2.9 showed greater immunogenicity and fewer adverse reactions. The Chinese State Food and Drug Administration (SFDA), which has a drug approval process similar to that of the US FDA, has approved PfCP2.9 for a Phase II Clinical Trial to be conducted in China’s YunnanProvince and in Southeast Asia.



About Sinobiomed



Sinobiomed Inc. is a leading Chinese developer of genetically engineered recombinant protein drugs and vaccines. Based in Shanghai, Sinobiomed currently has 10 products approved or in development: two on the market, one approved and market ready, four in clinical trials and three in research and development. The Company’s products respond to a wide range of diseases and conditions, including: malaria, hepatitis, surgical bleeding, cancer, rheumatoid arthritis, diabetic ulcers and burns, and blood cell regeneration. www.sinobiomed.com



Sinobiomed Investor Relations

R.Shane Starnes

Toll Free: 1-866-588-0829

Email: [e-mail]

[Salem88]

Wissenswert sollte sein, dass es, anders als behauptet, kein Patent in den Datanbanken gibt.

TREFFERLISTE
0 Treffer wurden in der Worldwide Datenbank gefunden für:
SINOBIOMED als Anmelder oder Erfinder
(Die Treffer sind nach dem Datum ihrer Aufnahme in die Datenbank geordnet.)
Das Ergebnis ist nicht das, was Sie erwartern. Unterstützung

Quelle
http://ep.espacenet.com/quickSearch?locale=de_EP

Datenbank Europäisches Patentamt.

[GordonGekko1974]

Antwort auf Beitrag Nr.: 30.858.300 von Salem88 am 26.07.07 13:15:26

so dann gib mal die nummer ein EPO patent number 1357128, dated July 4, 2007

[GordonGekko1974]

"
Erfinder: PAN WEIQING (CN) Anmelder: SECOND MILITARY MEDICAL UNIVER (CN)
ECLA: C07K14/445 IPC: C07K14/445; C12N1/21; A61K39/00 (+7)
Veröffentlichungsdaten
und wo meinst du wo der beschäftigt ist?Langsam nervst du mich Salem

[GordonGekko1974]

EPO patent number 1357128, dated July 4, 2007, has been assigned to the Second Military Medical University (SMMU) of Shanghai China for the preparation and dosage of plasmodium fusion antigen invented by Dr. Weiqing Pan. Dr. Pan, an advisor to Sinobiomed and an internationally recognized researcher, heads the Department of Parasitology at SMMU and serves on China’s national committee to combat parasitic diseases. The U.S. Patent and Trademark Office granted SMMU a patent for the plasmodium fusion antigen in September 2006.
WILLST DU HIER BILLIG REIN ODER WARUM WILLST DU UNS NERVÖS MACHEN??
Wenn du die Nummer bei Europaischen amt eingibst springen die daten schon rausSo wie oben geschrieben